Corporate Overview AUGUST 2022 Disclaimer This presentation has been prepared by Centessa Pharmaceuticals plc (the "Company") for informational purposes only and not for any other purpose. This presentation does not contain all the information that is or may be material to investors or potential investors and should not be considered as advice or a recommendation to investors or potential investors in respect of the holding, purchasing or selling of securities or other financial instruments and does not tak ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-04321 CENTESSA PHARMACEUTICALS PLC (Exact name of registrant as specified in its charter) England and Wales 98- ...

Financial Position - As of March 31, 2022, the company had cash and cash equivalents of $544.5 million, expected to fund operations to mid-2024 without additional capital [131]. - As of March 31, 2022, the Company had cash and cash equivalents of $544.5 million, following a $250.0 million Series A convertible preferred financing and an IPO that generated net proceeds of $344.1 million [156][164]. - The company had $75 million in debt principal outstanding under the Oberland Facility as of March 31, 2022 [186]. - Interest income from cash and cash equivalents was $0.1 million for the three months ended March 31, 2022 [185]. - Approximately 48% of the company's cash-based costs are denominated in currencies other than the US dollar, primarily GBP and Euro [187]. Revenue and Profitability - The company has not generated any revenue and relies on successful development and commercialization of product candidates for future profitability [133]. - The successful development of current or future product candidates remains highly uncertain, with numerous risks affecting costs and timelines [137]. Research and Development - The company aims to have four registrational programs by 2024, with ongoing trials for lixivaptan in Autosomal Dominant Polycystic Kidney Disease and planned trials for SerpinPC in Hemophilia B [114][116]. - The company has two programs with established clinical proof of concept and anticipates four emerging programs to achieve clinical proof of concept within the next 18 months [114]. - The company is pursuing opportunities for rapid development, including orphan drug designation and fast track designation, for its product candidates [114]. - Research and development expenses for the Company (Successor) for the three months ended March 31, 2022, were $36.9 million, a significant increase from $10.1 million for the same period in 2021 [151]. - The increase in research and development expenses was primarily due to higher development costs for Lixivaptan ($8.0 million) and increased personnel costs ($5.9 million) attributed to a rise in headcount and share-based compensation [151]. - The Company expects research and development expenses to increase significantly over the next several years due to rising personnel costs and clinical trial expenses [136]. - The Company participates in research tax incentive programs, which may provide cash refunds that reduce research and development expenses [140]. Financial Performance - The net loss for the Company (Successor) for the three months ended March 31, 2022, was $54.5 million, compared to a net loss of $238.7 million for the same period in 2021 [148]. - During the three months ended March 31, 2022, the Company used $50.0 million in net cash for operating activities, reflecting a net loss of $54.5 million [161]. - The Company reported a net cash used in investing activities of $(0.2) million for the three months ended March 31, 2022, primarily due to the purchase of property and equipment [163]. - Financing activities provided $0.1 million in net cash during the three months ended March 31, 2022, mainly from the exercise of stock options [164]. - The Company recorded noncash net charges of $6.8 million for share-based compensation and other adjustments during the three months ended March 31, 2022 [161]. Operational Challenges - The company has incurred recurring losses and negative cash flows from operations since inception, primarily funded through the sale of common and convertible preferred stock [131]. - The company has discontinued several programs, including small molecule inhibitors for Non-Small Cell Lung Cancer, and is winding down operations of certain subsidiaries [125]. - The company is actively monitoring the impact of COVID-19 on its clinical programs, with some modest delays in enrollment rates and supply chain activities [129]. - The Company anticipates that its funding requirements will increase significantly due to various factors, including clinical trial costs and regulatory review processes [166][167]. - The Company is unable to estimate exact working capital requirements due to uncertainties in research, development, and commercialization of product candidates [167]. Leadership and Governance - The company has strengthened its leadership team with key appointments, including Antoine Yver as Executive Vice President and Javad Shahidi as Chief Medical Officer [118]. Debt and Financing - The Company has entered into a Note Purchase Agreement with Oberland Capital for up to $300.0 million in senior secured notes, with an initial interest rate of 8.0% per annum [177]. - The fair value of the Note Purchase Agreement is based on estimated future payments, including interest and contingent milestone payments [179]. - The interest rate for the Notes was 8.00% per annum in the first quarter of 2022, with a potential increase of $750k annually for a 100 basis points rise in interest rates [186].

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-04321 CENTESSA PHARMACEUTICALS PLC (Exact name of registrant as specified in its charter) England and Wales 98-1612 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-04321 CENTESSA PHARMACEUTICALS PLC (Exact name of registrant as specified in its charter) England and Wale ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-04321 CENTESSA PHARMACEUTICALS PLC (Exact name of registrant as specified in its charter) England and Wales Not ...